Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Arcellx Inc. | CART-ddBCMA - (iMMagine-1) | Multiple Myeloma | Phase 2 | Data Released | Intravenous | Oncology |
| Arcturus Therapeutics Holdings Inc. | Kostaive (ARCT-154) | COVID-19 variant vaccine | Phase 3 | Data Released | Oral | COVID-19 |
| Arcturus Therapeutics Holdings Inc. | ARCT-032 - (LUNAR-CF) | Cystic Fibrosis | Phase 2 | Data Released | Inhalation | Respiratory |
| Arcturus Therapeutics Holdings Inc. | ARCT-810 - (LUNAR-OTC) | Ornithine Transcarbamylase (OTC) deficiency | Phase 2 | Ongoing | Intravenous | Genetic Disorder |
| Arcus Biosciences Inc. | Domvanalimab (AB154) + Zimberelimab (AB122) - (ARC-7) | Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Arcus Biosciences Inc. | Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10) | Non Small Cell Lung Cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Arcus Biosciences Inc. | Quemliclustat (AB680) - (PRISM-1) | Untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) | Phase 3 | Enrollment Conclusion | Intravenous | Oncology |
| Arcus Biosciences Inc. | Domvanalimab (AB154) and IMFINZI (Durvalumab) - (PACIFIC-8) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
